Biocartis appoints new CEO
This article was originally published in Clinica
Swiss molecular diagnostics company Biocartis has appointed Nayan Gregory Parekh CEO. He replaces current head and company co-founder Rudi Pauwels, who will become executive chairman and focus on the firm's scientific and technology strategy. Dr Parekh has been an executive director on Biocartis's board since April. His experience is mainly in financing and investment; Dr Parekh was most recently at New Rhein Healthcare, an investment firm which he co-founded. Prior to this, he spent six years as head of corporate development at Novartis, where he led the company's investments across different product areas and in various emerging markets.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.